Literature DB >> 22025191

Coexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma.

M Satoh1, M Vazquez-Del Mercado, M E Krzyszczak, Y Li, A Ceribelli, R W Burlingame, T T Webb, E S Sobel, W H Reeves, E K L Chan.   

Abstract

Anti-RNA polymerase III (RNAP III) antibodies are highly specific for scleroderma (SSc) and associated with diffuse SSc and renal crisis. Coexistence of anti-RNAP III and other SSc autoantibodies is rarely documented. We report three cases with coexisting anti-RNAP III and anti-U1RNP. Autoantibodies in 3829 sera from rheumatology clinics were screened by immunoprecipitation. Anti-RNAP III-positive sera were also examined by immunofluorescence and anti-RNAP III ELISA. In total, 35 anti-RNAP III-positive sera were identified by immunoprecipitation, in which three had coexisting anti-U1RNP. All three were anti-RNAP III ELISA positive. Two had anti-RNAP I dominant (vs. RNAP III) reactivity and showed strong nucleolar staining. A case with anti-U1/U2RNP (U2RNP dominant) had systemic lupus erythematosus (SLE)-SSc overlap syndrome; however, the remaining two cases had SLE without signs of SSc. All three cases of anti-RNAP III + U1RNP fulfilled ACR SLE criteria but none in the group with anti-RNAP III alone (p = 0.0002). In contrast, only one case in the former group had sclerodermatous skin changes and Raynaud's phenomenon, vs. 92% with scleroderma in the latter (p < 0.05). Although anti-RNAP III is highly specific for SSc, cases with coexisting anti-U1RNP are not so uncommon among anti-RNAP III positives (8%, 3/35) and may be SLE without features of SSc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025191      PMCID: PMC3608688          DOI: 10.1177/0961203311422712

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  30 in total

1.  The U2 small nuclear ribonucleoprotein particle as an autoantigen. Analysis with sera from patients with overlap syndromes.

Authors:  J Craft; T Mimori; T L Olsen; J A Hardin
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

2.  Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma.

Authors:  T G Phan; A Cass; A Gillin; P Trew; N Fertig; A Sturgess
Journal:  J Rheumatol       Date:  1999-11       Impact factor: 4.666

Review 3.  Renal crisis in asclerodermic scleroderma--lupus overlap syndrome.

Authors:  H C Horn; P Ottosen; P Junker
Journal:  Lupus       Date:  2001       Impact factor: 2.911

4.  Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients.

Authors:  H Poormoghim; M Lucas; N Fertig; T A Medsger
Journal:  Arthritis Rheum       Date:  2000-02

5.  Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis.

Authors:  A Bardoni; P Rossi; R Salvini; F Bobbio-Pallavicini; R Caporali; C Montecucco
Journal:  Clin Exp Rheumatol       Date:  2003 May-Jun       Impact factor: 4.473

6.  Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice.

Authors:  Hideo Yoshida; Minoru Satoh; Krista M Behney; Chee-Gun Lee; Hanno B Richards; Victoria M Shaheen; Jun-Qi Yang; Ram R Singh; Westley H Reeves
Journal:  Arthritis Rheum       Date:  2002-08

7.  Autoantibody reactive with RNA polymerase III in systemic sclerosis.

Authors:  Y Okano; V D Steen; T A Medsger
Journal:  Ann Intern Med       Date:  1993-11-15       Impact factor: 25.391

8.  Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III.

Authors:  M Hirakata; Y Okano; U Pati; A Suwa; T A Medsger; J A Hardin; J Craft
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Autoantibodies to the U2 small nuclear ribonucleoprotein in a patient with scleroderma-polymyositis overlap syndrome.

Authors:  T Mimori; M Hinterberger; I Pettersson; J A Steitz
Journal:  J Biol Chem       Date:  1984-01-10       Impact factor: 5.157

10.  Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study.

Authors:  Olivier Meyer; Luc De Chaisemartin; Pascale Nicaise-Roland; Jean Cabane; Florence Tubach; Philippe Dieude; Gilles Hayem; Elisabeth Palazzo; Sylvie Chollet-Martin; André Kahan; Yannick Allanore
Journal:  J Rheumatol       Date:  2009-11-16       Impact factor: 4.666

View more
  3 in total

1.  Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes.

Authors:  Kristina E N Clark; Corrado Campochiaro; Lauren V Host; Alper Sari; Jennifer Harvey; Christopher P Denton; Voon H Ong
Journal:  Sci Rep       Date:  2022-07-02       Impact factor: 4.996

Review 2.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

3.  SNRPA enhances tumour cell growth in gastric cancer through modulating NGF expression.

Authors:  Ning Dou; Dong Yang; Shijun Yu; Binghao Wu; Yong Gao; Yandong Li
Journal:  Cell Prolif       Date:  2018-07-24       Impact factor: 6.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.